More recently, Seavey and colleagues developed an oral listeriolysin-mVEGFR2 DNA vaccine that resulted in marked anti-tumor CTL-mediated inhibition of Her-2-expressing breast cancer tumors (NT-2) in mice [32]. Here, ERBB2 is linked to neoplasm.